FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947285962> ?p ?o ?g. }

• W2947285962 abstract "e12116 Background: patients with locally-advanced triple negative breast cancer (TNBC) have dismal prognosis with current standard of care therapy. Pathologic complete response (pCR) is the most important prognostic factor for long-term survival of these patients. Methods: this was non-randomized prospective single-center phase II study. Key inclusion criteria were histologically verified locally advanced TNBC, non-eligibility for primary surgical treatment (ie, TNM stage Т 2-4 N 2-3 M 0 ) and no evidence of metastatic disease. Patients were treated with 8 cycles of neoadjuvant doxorubicine, paclitaxel and cisplatin chemotherapy (ATP; doxorubicine 40 mg/m2 day 1, paclitaxel 160 mg/m2 day 1 and cisplatin 50 mg/m2 day 1 every two weeks) with G-CSF support (filgrastim 5 mcg/kg day 2-6). After 8 cycles of chemotherapy patients were referred for surgical treatment; adjuvant radiation therapy was prescribed to all patients. Primary end point was pCR assessed in modified intention-to-treat population (ie, in patients who underwent surgical treatment). Key secondary endpoints were disease-free survival (DFS) and pCR rate according to BRCA status. Results: we enrolled 80 patients, 79 (98.7%) of them underwent surgical treatment and were included in the analysis. Median age was 46 years (25-68), 22 (27.1%) patients had BRCA1 mutations, 5382insC was the most common mutation (17 [77.2%] of patients); 1 (1.2%) patient had CHEK2 mutation. pCR was achieved in 51 (64.5%) patients. In with BRCA1-mutation carriers pCR rate was 61.9%, in patients with 5382insC – 81.2%. 2-year DFS was 77.3%; 2-year overall survival was 91.0% . Most common grade 3-4 adverse events were anemia (29.3%), neutropenia (17.8%), neuropathy (4.9%), stomatitis (3.7%) and thrombocytopenia (1.8%). Conclusions: the ATP regimen was effective in treatment of locally-advanced TNBC, especially in patients with founder 5382insC BRCA1 mutation for Slavic population and deserves further investigation." @default.
• W2947285962 created "2019-06-07" @default.
• W2947285962 creator A5012700479 @default.
• W2947285962 creator A5028263106 @default.
• W2947285962 creator A5029722624 @default.
• W2947285962 creator A5030337844 @default.
• W2947285962 creator A5034196481 @default.
• W2947285962 creator A5034246940 @default.
• W2947285962 creator A5045467858 @default.
• W2947285962 creator A5088282537 @default.
• W2947285962 date "2019-05-20" @default.
• W2947285962 modified "2023-10-02" @default.
• W2947285962 title "Efficacy and safety of intensified platinum-based neoadjuvant chemotherapy in locally advanced triple-negative breast cancer: Preliminary results of non-randomized phase II study." @default.
• W2947285962 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e12116" @default.
• W2947285962 hasPublicationYear "2019" @default.
• W2947285962 type Work @default.
• W2947285962 sameAs 2947285962 @default.
• W2947285962 citedByCount "1" @default.
• W2947285962 countsByYear W29472859622020 @default.
• W2947285962 crossrefType "journal-article" @default.
• W2947285962 hasAuthorship W2947285962A5012700479 @default.
• W2947285962 hasAuthorship W2947285962A5028263106 @default.
• W2947285962 hasAuthorship W2947285962A5029722624 @default.
• W2947285962 hasAuthorship W2947285962A5030337844 @default.
• W2947285962 hasAuthorship W2947285962A5034196481 @default.
• W2947285962 hasAuthorship W2947285962A5034246940 @default.
• W2947285962 hasAuthorship W2947285962A5045467858 @default.
• W2947285962 hasAuthorship W2947285962A5088282537 @default.
• W2947285962 hasConcept C121608353 @default.
• W2947285962 hasConcept C126322002 @default.
• W2947285962 hasConcept C143998085 @default.
• W2947285962 hasConcept C168563851 @default.
• W2947285962 hasConcept C2776694085 @default.
• W2947285962 hasConcept C2780110267 @default.
• W2947285962 hasConcept C2992734768 @default.
• W2947285962 hasConcept C530470458 @default.
• W2947285962 hasConcept C71924100 @default.
• W2947285962 hasConceptScore W2947285962C121608353 @default.
• W2947285962 hasConceptScore W2947285962C126322002 @default.
• W2947285962 hasConceptScore W2947285962C143998085 @default.
• W2947285962 hasConceptScore W2947285962C168563851 @default.
• W2947285962 hasConceptScore W2947285962C2776694085 @default.
• W2947285962 hasConceptScore W2947285962C2780110267 @default.
• W2947285962 hasConceptScore W2947285962C2992734768 @default.
• W2947285962 hasConceptScore W2947285962C530470458 @default.
• W2947285962 hasConceptScore W2947285962C71924100 @default.
• W2947285962 hasLocation W29472859621 @default.
• W2947285962 hasOpenAccess W2947285962 @default.
• W2947285962 hasPrimaryLocation W29472859621 @default.
• W2947285962 isParatext "false" @default.
• W2947285962 isRetracted "false" @default.
• W2947285962 magId "2947285962" @default.
• W2947285962 workType "article" @default.